[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]

V Le Moing; Z Eid; J L Ecobichon; X Duval; P Longuet; C Elbim; F Brun-Vezinet; C Leport; J L Vilde

[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]

Ann Med Interne (Paris). 2001 Feb;152(1):11-4.

[Article in French]

Authors

V Le Moing¹, Z Eid, J L Ecobichon, X Duval, P Longuet, C Elbim, F Brun-Vezinet, C Leport, J L Vilde

Affiliation

¹ Service des Maladies Infectieuses et Tropicales, Hôpital Bichat--Claude Bernard, Paris.

PMID: 11240420

Abstract

From March to July 1996, 61 patients with CD4<50/mm(3)began a therapy with protease inhibitors. Increase and maintenance of CD4>100/mm(3) was observed in 39/61 patients with a protective effect for occurrence of AIDS or death. This immunological response was correlated with the duration of the virological response. However, 38% of patients with long-term immunological response never had a undetectable viral load.

Publication types

English Abstract

MeSH terms

CD4 Lymphocyte Count*
Disease Progression
Follow-Up Studies
HIV Infections / blood
HIV Infections / drug therapy*
HIV Infections / immunology*
HIV Infections / mortality
HIV Infections / virology
HIV Protease Inhibitors / immunology*
HIV Protease Inhibitors / therapeutic use*
Humans
Indinavir / immunology*
Indinavir / therapeutic use*
Ritonavir / immunology*
Ritonavir / therapeutic use*
Saquinavir / immunology*
Saquinavir / therapeutic use*
Time Factors
Treatment Outcome
Viral Load

Substances

HIV Protease Inhibitors
Indinavir
Saquinavir
Ritonavir